Literature DB >> 7116300

Toxicity of very high dose nitrosourea administration.

J H Breeden, J T Vollmer, P L Twomey.   

Abstract

We report a case of inadvertent administration of over twice the usual dose of methyl-CCNU. The patient exhibited an early onset of bone marrow suppression. Profound pancytopenia, including lymphopenia, persisted for over seven weeks, Although early recovery started at about five weeks. Permanent marrow damage was indicated by persistent thrombocytopenia and abnormal megakaryocyte morphology at autopsy, some six months after the single exposure to methyl-CCNU. There was no discernible toxicity to lung, liver, or kidneys. The case suggests that the cummulative bone marrow toxicity seen with nitrosoureas is not dose-schedule sensitive. There is also evidence suggesting that high dose nitrosourea therapy affects a bone marrow target population other than the early stem cell target affected by usual doses of these drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116300     DOI: 10.1002/1097-0142(19821101)50:9<1728::aid-cncr2820500913>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  1 in total

1.  Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.

Authors:  Augusto Pessina; Arianna Bonomi; Valentina Coccè; Gloria Invernici; Stefania Navone; Loredana Cavicchini; Francesca Sisto; Maura Ferrari; Lucia Viganò; Alberta Locatelli; Emilio Ciusani; Graziella Cappelletti; Daniele Cartelli; Caruso Arnaldo; Eugenio Parati; Giovanni Marfia; Roberto Pallini; Maria Laura Falchetti; Giulio Alessandri
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.